Glucocorticoid-Induced Osteoporosis: The Potential Role of Romosozumab
Glucocorticoid (GC)-induced osteoporosis (GIOP) is a major problem in patients with rheumatic diseases. The deleterious effect of GC on bone turnover is rapid and dose-dependent, with a predilection on the trabecular bone, resulting in vertebral fractures. Early recognition and prompt treatment of G...
Main Authors: | Jacqueline So, Chi Chiu Mok |
---|---|
Format: | Article |
Language: | English |
Published: |
World Scientific Publishing
2020-12-01
|
Series: | Journal of Clinical Rheumatology and Immunology |
Subjects: | |
Online Access: | http://www.worldscientific.com/doi/epdf/10.1142/S2661341720300074 |
Similar Items
-
Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Chuanjian Yuan, et al.
Published: (2023-06-01) -
Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
by: Yasuaki Hirooka, et al.
Published: (2021-09-01) -
Anabolic therapy for osteoporosis: update on efficacy and safety
by: Leonardo Bandeira, et al.
Published: (2022-12-01) -
Papel del Romosozumab en la práctica clínica a la luz de la evidencia
by: Alejandro Román-González, et al.
Published: (2022-01-01) -
Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report
by: Masafumi Kashii, et al.
Published: (2020-12-01)